↓ Skip to main content

Cochrane Database of Systematic Reviews

Bisphosphonates and other bone agents for breast cancer

Overview of attention for article published in this source, February 2012
Altmetric Badge

Mentioned by

1 policy source
6 tweeters
1 Facebook page


172 Dimensions

Readers on

160 Mendeley
Bisphosphonates and other bone agents for breast cancer
Published by
John Wiley & Sons, Ltd, February 2012
DOI 10.1002/14651858.cd003474.pub3
Pubmed ID

Wong, Matthew HF, Stockler, Martin R, Pavlakis, Nick


Bone is the most common site of metastatic disease associated with breast cancer (BC). Bisphosphonates inhibit osteoclast-mediated bone resorption, and novel targeted therapies such as denosumab, inhibit key pathways in the vicious cycle of bone metastases.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 160 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 1%
Spain 1 <1%
France 1 <1%
Canada 1 <1%
Unknown 155 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 31 19%
Student > Master 24 15%
Student > Ph. D. Student 20 13%
Other 17 11%
Student > Bachelor 15 9%
Other 29 18%
Unknown 24 15%
Readers by discipline Count As %
Medicine and Dentistry 88 55%
Agricultural and Biological Sciences 8 5%
Nursing and Health Professions 7 4%
Psychology 5 3%
Pharmacology, Toxicology and Pharmaceutical Science 3 2%
Other 12 8%
Unknown 37 23%